Agendia Establishes Contract with Humana to Cover MammaPrint

Irvine, California and Amsterdam (ots/PRNewswire) -
Agendia, a world leader in molecular cancer diagnostics, announced
today that it has established a contract with leading insurance
provider Humana to reimburse for the company's MammaPrint test.
Agendia's contract with Humana expands the coverage for MammaPrint by
more than 17 million lives. In November 2009, Palmetto GBA,
California's Part B Medicare administrator, established coding
guidelines for MammaPrint, allowing healthcare providers from across
the United States to submit claims for the test. MammaPrint is the
first and only FDA-cleared breast cancer recurrence test available
and has been reimbursed by payors since 2008.

"Humana is dedicated to advancing excellence in healthcare
delivery on behalf of its members. This commitment to quality care
and patient safety has now led Humana to include MammaPrint in its
medical benefit management program," said Bernhard Sixt, Chief
Executive Officer of Agendia. "We are proud that Humana is offering
its members coverage for the only gene expression test for breast
cancer recurrence which has been cleared by the FDA."

Humana, headquartered in Louisville, Kentucky, is one of the
nation's largest publicly traded health and supplemental benefits
companies, with approximately 10.4 million medical members and
approximately 7.2 million specialty-benefit members. Humana is a
full-service benefits-solutions company, offering a wide array of
health and supplementary benefit plans for employer groups,
government programs and individuals.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA clearance
requires clinical and analytical validation and reporting systems to
ensure patient safety issues are addressed. Highly accurate,
MammaPrint identifies patients with early metastasis risk - patients
who are likely to develop metastases within five years following
surgery. Several authoritative studies have shown that chemotherapy
particularly reduces early metastasis risk. In planning treatment,
the MammaPrint test results provide doctors with a clear rationale to
assess the benefit of chemotherapy in addition to other clinical
information and pathology tests. All MammaPrint tests are conducted
in Agendia's CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. Agendia is based in Irvine, California, and in
Amsterdam, the Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Media Contacts: Hans Herklots, Agendia, +31-20-462-1557
(Office),+31-620-083-509 (Mobile), hans.herklots@agendia.com; Todd
Aydelotte,Ricochet Public Relations, +1-212-679-3300 x111 Office,
todd@ricochetpr.com